CancerRop said Wednesday that it has signed a cooperative agreement with Cannis, a Malaysian company, to advance its products such as genetic testing, cosmetics and probiotics, to the Southeast Asian country.
Cannis provides a smartphone-based application platform in Malaysia and has an online technical team, including blockchain, in Hangzhou, China, and is preparing to be listed on the NASDAQ stock market in 2021. Cannis App, the company’s main application, runs real-time e-commerce, online games, internet live broadcast and Cannis pay. The company aims to increase its members from five million to 30 million within three years.
The agreement comes after the Malaysian company selected CancerRop as its official partner during its periodic seminar on Sunday.
Under the accord, CancerRop has become an exclusive partner in probiotics and cosmetics using genetic testing in Cannis' real-time e-commerce. Cannis is already carrying out follow-up measures to sell CancerRop’s product in Malaysia.
“Cannis has recorded annual sales of about $52.9 million (60 billion won) since it became fully operational this year,” a Cannis official said. “The company has decided to support CancerRop's genetic testing, including probiotics and cosmetics, as a cultivating product next year.”
CancerRop CEO Lee Jang-woo also said, “Estimated revenues from the collaboration are estimated at 30 billion won -- 10 billion won for probiotics, 15 billion won for cosmetics and 5 billion won for genetic analysis. Our company expects sales will continue to grow every year through Cannis’ online mall.”
<© Korea Biomedical Review, All rights reserved.>